Advanced nanomaterials in prognostic implication of oncogenic role of CDCA7 and GALNT6 for bladder cancer treatment

Cell division cycle associated 7 (CDCA7) functions in Myc-mediated tumorigenesis. Glycosylation, which is frequently altered in malignancies, is regulated by polypeptide N-acetylgalactosaminyltransferase 6 (GALNT6) and is crucial for cancer growth. However, their prognostic value and biological roles in bladder cancer (BLCA) remain unknown. The primary objective of this research is to investigate the potential applications of cutting-edge nanomaterials in the therapeutic management of bladder cancer. A key focus of the study is to thoroughly examine the influence and involvement of the CDCA7 and GALNT6 genes in the treatment process. We assessed clinicopathological traits and prognostic value of CDCA7 and GALNT6 in BLCA.CDCA7 and GALNT6 were overexpressed in BLCA tissues from TCGA-BLCA datasets. Changes in BLCA were associated with DNA-binding transcription activator activity, mitotic cell cycle phase changes, transcription regulator complex, p53 signaling pathway, cell cycle, and pathways associated with transcriptional dysregulation in cancer. Survival analysis showed that they were crucial to the incidence and prognosis of BLCA. The expression levels of CDCA7 and GALNT6 were significantly correlated with the therapeutic effect of nanomaterials, and their down-regulation could enhance the anti-tumor effect of nanomaterials. Patients with BLCA who expressed high CDCA7 and GALNT6 levels had poorer disease outcome compared with patients with low levels.These findings have new implications for precision therapy and individualized risk stratification that will benefit patients with BLCA.